Varagić V M
Srp Arh Celok Lek. 1992 Jun;120 Suppl 4:1-4.
Introduction of adrenergic beta-blockers into medical therapy is an exceptionally good example of how a clear scientific background and a perfect knowledge about physiological and pathophysiological functions may help to plan and accomplish a pharmacological investigation in order to introduce new drugs. Several scientific contributions have helped development of adrenergic beta-blockers: R. Ahlquist with his discovery of adrenergic beta-receptors, U.von Euler with the discovery of the adrenergic neurotransmitter noradrenaline, J. Axelrod with the discovery of catecholamine metabolism, E. Sutherland with the discovery of the molecular nechanism of beta-receptor functioning, and last, but not least, Sir James Black with the discovery and successfull introduction of first adrenergic beta-blockers into medical therapy. Except R. Ahlquist, all others were awarded the Nobel prizes in Physiology or Medicine. Beta-blockers are among the most significant contributions to modern pharmacotherapy. If nothing spectacular happens during the next several yearx of this century, then the adrenergic beta-blockers will remain among the top ten pharmacological discoveries in the 20th century. This Pharmacotherapeutic Symposium on Beta-Blockers shows the achievements in clinical application of adrenergic beta-blockers in various Medical specialities during the last 10 years.
将肾上腺素能β受体阻滞剂引入医学治疗是一个非常好的例子,说明了清晰的科学背景以及对生理和病理生理功能的完美了解如何有助于规划和完成一项药理学研究,从而引入新药。多项科学贡献推动了肾上腺素能β受体阻滞剂的发展:R. 阿尔奎斯特发现了肾上腺素能β受体;U. 冯·欧勒发现了肾上腺素能神经递质去甲肾上腺素;J. 阿克塞尔罗德发现了儿茶酚胺代谢;E. 萨瑟兰发现了β受体功能的分子机制;最后但同样重要的是,詹姆斯·布莱克爵士发现并成功将首批肾上腺素能β受体阻滞剂引入医学治疗。除R. 阿尔奎斯特外,其他人均获得了诺贝尔生理学或医学奖。β受体阻滞剂是现代药物治疗最重要的贡献之一。如果在本世纪接下来的几年里没有什么惊人的事情发生,那么肾上腺素能β受体阻滞剂将仍然是20世纪十大药理学发现之一。本次β受体阻滞剂药物治疗研讨会展示了过去10年中肾上腺素能β受体阻滞剂在各种医学专科临床应用中的成就。